Diabetic Foot Care and PRP in India: Protecting Feet When Standard Care Falls Short | ALIV

Diabetic foot ulcers are among the most serious complications of diabetes — they affect approximately 15% of all people with diabetes in India during their lifetime, and are responsible for the majority of the 40,000+ lower-limb amputations performed annually in India. The tragedy is that many of these amputations are preventable — not with miraculous new technology, but through better integrated clinical management of the biological healing failure that drives ulcer non-healing. ALIV's regenerative approach to diabetic foot care — using PRP and, in appropriate cases, ACT — addresses the growth factor deficit at the heart of this healing failure.

Why Diabetic Foot Ulcers Don't Heal: The Biology of Failure

The normal healing cascade — from haemostasis through inflammatory, proliferative, and remodelling phases — is disrupted at multiple levels in diabetes. Neutrophils (the infection-fighting first responders) are functionally impaired in hyperglycaemia, making initial infection defence inadequate. Macrophages — which normally transition from inflammatory (M1) to healing-supportive (M2) phenotype as healing progresses — remain locked in the inflammatory M1 state in the diabetic wound environment, preventing the proliferative phase from initiating. Growth factors (PDGF, VEGF, EGF) are either inadequately produced or rapidly degraded by the elevated MMP (matrix metalloproteinase) levels in chronic diabetic wound fluid. Peripheral neuropathy means the patient cannot feel the wound progressing; peripheral vascular disease means blood supply to deliver repair cells and growth factors is inadequate. The result is a wound that cannot heal through its normal biological process — it needs external growth factor support to substitute for what the diabetic environment cannot produce.

PRP in Diabetic Foot Care: The Evidence

PRP for diabetic foot ulcers has one of the more robust evidence bases in regenerative wound care. A 2020 meta-analysis in the International Wound Journal found significantly higher complete healing rates and shorter healing times in PRP-treated diabetic foot ulcers compared to standard care alone. The mechanism is direct: PRP delivers the PDGF, VEGF, and TGF-β that the diabetic wound environment cannot produce or sustain — providing the growth factor stimulus for macrophage M2 transition, fibroblast activation, and neovascularisation that standard wound care cannot supply. PDGF specifically has a US FDA-approved pharmaceutical form for diabetic foot ulcers (becaplermin gel) — the evidence for the specific growth factor is established; PRP is an autologous, richer source of the same factor. See: ACT for chronic wound healing for the broader wound care context.

The Integrated Diabetic Foot Protocol at ALIV

PRP or ACT for a diabetic foot ulcer does not replace — it augments — the standard diabetic foot care protocol. ALIV's integrated approach for diabetic foot patients includes: confirmation of adequate glycaemic control (the healing environment cannot be supported against ongoing severe hyperglycaemia); vascular assessment and referral for revascularisation where indicated (PRP cannot overcome severe ischaemia — restoring blood flow is the prerequisite); infection assessment and targeted antibiotic management where infection is present; appropriate wound debridement to remove non-viable tissue and expose the healthy wound bed to the growth factor signal; appropriate offloading (pressure relief from the wound bed — cast, footwear modification, or bed rest as appropriate); and then PRP delivery to the debrided, clean, perfused wound bed. The growth factor therapy succeeds only in this prepared context — it is not a standalone cure for a wound that has not received adequate foundational care.

How is PRP applied to a diabetic foot wound?

PRP for diabetic foot ulcers is applied through peri-wound intradermal injection — delivering growth factors into the wound margins and bed through targeted injections rather than surface application. In some protocols, a PRP-soaked dressing or PRP matrix may be applied to the wound surface for sustained growth factor delivery between sessions. The specific delivery method depends on wound size, depth, and location. All wound PRP procedures are performed in ALIV's clinical setting under sterile conditions with appropriate wound care before and after the growth factor delivery.

How often does PRP need to be applied to a diabetic foot wound?

Chronic wounds typically require two to four PRP applications at one to two week intervals as an initial course. Wound response is assessed between applications — improving wound bed appearance, increasing granulation tissue, and measurable reduction in wound area are the objective response markers. The frequency and total number of applications are adjusted based on the clinical response trajectory. In responsive wounds, meaningful healing progression is typically visible by three to four weeks after the first application; wounds that show no response at four to six weeks are reassessed for whether the prerequisite conditions (adequate blood flow, infection control, offloading) are fully in place.

Can ALIV coordinate with my diabetic care team for foot wound management?

Yes — and ALIV strongly encourages this coordination. The treating diabetologist, endocrinologist, and potentially a vascular surgeon are integral parts of the care team for diabetic foot patients. ALIV provides written clinical documentation of the PRP protocol for any treating physician who wishes to be informed. The glycaemic management during the wound care period, the assessment for peripheral arterial disease, and any systemic antibiotic decisions are properly made by the primary care team — ALIV's role is the regenerative wound care component within that coordinated framework